The stock has a 36-month beta value of 0.70. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NDRA is 0.52M, and at present, short sellers hold a 4.62% of that float. On November 21, 2024, the average trading volume of NDRA was 323.13K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NDRA) stock’s latest price update
The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) has jumped by 7.64 compared to previous close of 4.71. Despite this, the company has seen a fall of -11.52% in its stock price over the last five trading days. businesswire.com reported 2024-11-15 that ANN ARBOR, Mich.–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its conti.
NDRA’s Market Performance
ENDRA Life Sciences Inc (NDRA) has experienced a -11.52% fall in stock performance for the past week, with a -65.35% drop in the past month, and a -67.46% drop in the past quarter. The volatility ratio for the week is 23.19%, and the volatility levels for the past 30 days are at 24.80% for NDRA. The simple moving average for the past 20 days is -32.06% for NDRA’s stock, with a -98.99% simple moving average for the past 200 days.
NDRA Trading at -33.73% from the 50-Day Moving Average
After a stumble in the market that brought NDRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.90% of loss for the given period.
Volatility was left at 24.80%, however, over the last 30 days, the volatility rate increased by 23.19%, as shares sank -56.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.96% lower at present.
During the last 5 trading sessions, NDRA fell by -11.52%, which changed the moving average for the period of 200-days by -99.72% in comparison to the 20-day moving average, which settled at $7.47. In addition, ENDRA Life Sciences Inc saw -99.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NDRA starting from UBS Group AG, who purchase 3,715 shares at the price of $0.55 back on Aug 27 ’24. After this action, UBS Group AG now owns 146,012 shares of ENDRA Life Sciences Inc, valued at $2,052 using the latest closing price.
Stock Fundamentals for NDRA
Current profitability levels for the company are sitting at:
- -15.1 for the present operating margin
- 0.61 for the gross margin
The net margin for ENDRA Life Sciences Inc stands at -20.58. The total capital return value is set at -0.86. Equity return is now at value -149.45, with -110.35 for asset returns.
Based on ENDRA Life Sciences Inc (NDRA), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -6.73.
Currently, EBITDA for the company is -9.78 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of -2.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
To sum up, ENDRA Life Sciences Inc (NDRA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
